as 11-21-2024 4:00pm EST
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Founded: | 2006 | Country: | United States |
Employees: | N/A | City: | WALTHAM |
Market Cap: | 111.2M | IPO Year: | N/A |
Target Price: | $8.80 | AVG Volume (30 days): | 343.7K |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.34 | EPS Growth: | N/A |
52 Week Low/High: | $3.78 - $16.65 | Next Earning Date: | 11-13-2024 |
Revenue: | $88,179,506 | Revenue Growth: | 40.40% |
Revenue Growth (this year): | 43.61% | Revenue Growth (next year): | 12.92% |
OPRX Breaking Stock News: Dive into OPRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
MT Newswires
8 days ago
MT Newswires
8 days ago
GuruFocus.com
8 days ago
Zacks
8 days ago
GlobeNewswire
8 days ago
Zacks
15 days ago
GlobeNewswire
22 days ago
The information presented on this page, "OPRX OptimizeRx Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.